Results 101 to 110 of about 419,374 (211)

Immune and Inflammatory Pathways in Non-Alcoholic Steatohepatitis (NASH). An update [PDF]

open access: yes, 2019
Non-alcoholic steatohepatitis (NASH), also known as fatty liver disease (FLD), is a major public health problem. It is considered to be the hepatic manifestation of the metabolic syndrome.
Breaban, Iulia   +10 more
core   +1 more source

Guanine nucleotide exchange factors activate Rab8a for Toll-like receptor signalling [PDF]

open access: bronze, 2019
Samuel J. Tong   +4 more
openalex   +1 more source

Expression of Toll-Like Receptor 2 on Human Schwann Cells: a Mechanism of Nerve Damage in Leprosy

open access: green, 2003
Rosane B. de Oliveira   +6 more
openalex   +1 more source

Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7

open access: green, 2009
Tomoko Hayashi   +8 more
openalex   +1 more source

Experimental immunology<br>The response of Toll-like receptors to glutamine in neonatal rat intestine [PDF]

open access: gold, 2013
Abdülbaki Karaoğlu   +8 more
openalex   +1 more source

A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages

open access: gold, 2021
Jiawen Zhang   +11 more
openalex   +1 more source

Toll-like receptor 3 signaling attenuated colitis-associated cancer development in mice [PDF]

open access: gold
Kian Fan Chung   +9 more
openalex   +1 more source

The role of hypoxia and complement receptor 2 or toll-like receptor 2 on B1 B cell effector function [PDF]

open access: yes
Master of ScienceDivision of BiologySherry D. FlemingProfessional phagocytes play a critical role in maintaining homeostasis within a host through phagocytic, microbicidal, and inflammatory activity.
Knights, Kaori
core   +1 more source

A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant

open access: hybrid, 2016
Judith Falloon   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy